On April 24, 2024 Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsy for the early detection of cancer, reported that it will present data at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting showing the performance of its Mercy Halo Ovarian Cancer screening test in a large cohort of asymptomatic, postmenopausal women (Press release, Mercy BioAnalytics, APR 24, 2024, View Source [SID1234642310]). The results of the study, which included more than 1,300 women, will be shared in a poster presentation on June 3rd, 2024.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Ovarian cancer is one of the leading causes of cancer death among women. More than 70% of ovarian cancer is diagnosed in women over 50 years of age, and nearly 80% of ovarian cancer is diagnosed at an advanced stage of disease, when survival is poor. Today, there are no guideline-recommended screening tests for ovarian cancer, which kills nearly 13,000 women each year in the US alone.
"Legacy technologies such as CA125 serum biomarker testing and transvaginal ultrasound imaging have not proven accurate enough to justify their use for population ovarian cancer screening. Unfortunately, no alternative technology has demonstrated superior clinical performance in a screening population since CA125 and transvaginal ultrasound were introduced nearly four decades ago," said Dawn Mattoon, PhD, Mercy’s CEO.
Mercy is developing a highly sensitive and specific screening test designed to help detect ovarian cancer earlier in asymptomatic, postmenopausal women. Mercy analyzed samples from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) in which 200,000 women were enrolled, randomized to no screening or annual screening, and followed for up to 20 years. All trial participants donated a blood sample at the time of enrollment. Mercy analyzed the blood of more than 1,300 trial participants to assess the sensitivity and specificity of the Mercy Halo test for detecting ovarian cancer up to three years prior to clinical diagnosis.
"This study allowed us to see how far in advance of the presentation of clinical disease our test can detect early-stage ovarian cancer, and at what sensitivity and specificity," Mattoon said. "We’re excited to share the outstanding performance of the Mercy Halo test in this large patient cohort that is representative of our intended patient population."
The Mercy Halo test achieves high sensitivity and specificity through the simultaneous detection of multiple cancer-related biomarkers co-localized on the surface of individual tumor-associated extracellular vesicles. The high abundance of extracellular vesicles in circulation enables the Mercy Halo test to be run on a very small volume of serum or plasma with a simple qPCR-based read-out, unlike cell-free DNA-based tests which typically require a larger volume of blood and next-generation sequencing to generate results.
The Mercy ovarian cancer data will be shared on June 3rd in a poster titled "Evaluation of a novel extracellular vesicle (EV) based ovarian cancer (OC) screening test in asymptomatic postmenopausal women."